Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials

Journal:

The Lancet Psychiatry

Published:

2025-11-13

DOI:

10.1016/s2215-0366(25)00296-2

Affiliations:

23

Authors:

22

Go to article

Institutions	Authors	Share
Boehringer Ingelheim International GmbH, Germany	3.500000	0.16
Boehringer Ingelheim Pharmaceuticals, Inc., United States of America (USA)	3.000000	0.14
Boehringer Ingelheim RCV GmbH & Co. KG, Austria	2.000000	0.09
Duke University Hospital, United States of America (USA)	1.000000	0.05
University of Miami (UM), United States of America (USA)	1.000000	0.05
Hokkaido University, Japan	1.000000	0.05
Neurocrine Biosciences Inc., United States of America (USA)	1.000000	0.05
Yale University, United States of America (USA)	1.000000	0.05
UCLA Health, United States of America (USA)	1.000000	0.05
National Institute of Mental Health (NIMH), NCNP, Japan	1.000000	0.05
Beijing Anding Hospital, Capital Medical University, China	1.000000	0.05
Peking University Sixth Hospital, PKUHSC, China	1.000000	0.05
Boehringer Ingelheim - France, France	1.000000	0.05
Boehringer Ingelheim (Canada) Ltd., Canada	1.000000	0.05
Columbia University Irving Medical Center (CUIMC), CU, United States of America (USA)	0.500000	0.02
Ludwig Maximilians University of Munich (LMU), Germany	0.333333	0.02
Max Planck Institute of Psychiatry, Germany	0.333333	0.02
DZPG partner site Munich-Augsburg, Germany	0.333333	0.02
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, United States of America (USA)	0.250000	0.01
Zucker Hillside Hospital, Northwell Health, United States of America (USA)	0.250000	0.01
Charité - University Medicine Berlin, Germany	0.250000	0.01
DZPG partner site Berlin-Potsdam, Germany	0.250000	0.01

Interested in Clinical Sciences?